ASX Share rice
Wed 21 Oct 2020 - 09:18:pm (Sydney)

KZA Share Price

KAZIA THERAPEUTICS LIMITEDKZAPharmaceuticals, Biotechnology & Life Sciences

KZA Company Information

Name:

Kazia Therapeutics Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

Three International Towers Sydney NSW Australia 2000

Phone:

1300 787 272

CEO, MD & Exec. Director:

Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (

Director of Fin. & Admin.:

Ms. Gabrielle Heaton

Company Sec.:

Ms. Catherine Jane Hill B.Sc., C.A., ACA, GAICD, BSc (Hons)

Director of Marketing & Communications:

Kym Robins

Company Overview:

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

KZA Share Price Information

Shares Issued:

115.15M

Market Capitalisation:

$96.73M

Revenue (TTM):

$0.99M

Revenue Per Share (TTM):

$0.01

Earnings per Share:

$-0.179

Operating Margin (TTM):

$-12.34

Return On Assets (TTM):

$-0.34

Return On Equity (TTM):

$-0.88

Quarterly Revenue Growth (YOY):

-0.461

Gross Profit(TTM):

$0.99M

Diluted Earnings Per Share (TTM):

$-0.171

KZA CashFlow Statement

CashFlow Date:

2020-06-30

Change To Liabilities:

$1.42M

Net Income:

$-12,467,470

Total Cash From Operating Activities:

$-8,809,520

Depreciation:

$1.08M

Sale Purchase Of Stock:

$12.14M

Capital Expenditures:

$0

KZA Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-12,765,660

Net Income:

$-12,467,470

Operating Income:

$-12,604,730

Other Operating Expenses:

$-2,259

Income Tax Expense:

$-298,195

Total Revenue:

$65.91K

KZA Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$12.41M

Total Liabilities:

$8.94M

Total Stockholder Equity:

$14.13M

Other Current Liabilities:

$1.39M

Total Assets:

$23.06M

Common Stock:

$48.78M

Other Current Assets:

$157.41K

Retained Earnings:

$-34,664,450

Other Liabilities:

$3.87M

Total Current Liabilities:

$5.07M

Net Tangible Assets:

$1.72M

Total Current Assets:

$10.65M

Net Receivables:

$440

Accounts Payable:

$1.69M

KZA Share Price History

KZA News

02 Sep, 2020
LONDON, UK / ACCESSWIRE / September 2, 2020 / We are reinitiating on Kazia Therapeutics (NASDAQ:KZIA), which is entering late-stage trials for its lead product, paxalisib, for glioblastoma multiforme (GBM).
01 Sep, 2020
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Kazia Therapeutics...
24 Aug, 2020
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Kazia's paxalisib (formerly GDC-0084) for the treatment of malignant glioma, which includes Diffuse Intrinsic Pontine Glioma (DIPG), a rare and highly aggressive childhood brain cancer.
20 Aug, 2020
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Kazia's paxalisib (formerly GDC-0084) for the treatment of glioblastoma, the most common and most aggressive form of primary brain cancer.
07 Aug, 2020
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia's paxalisib (formerly GDC-0084) for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG), a rare and highly-aggressive childhood brain cancer.
22 Jun, 2020
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share poster presentations of interim data from the ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most common and most aggressive form of primary brain cancer, and from the phase I study of Cantrixil in ovarian cancer.
01 Jun, 2020
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share a poster presentation of interim data from the ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most common and most aggressive form of primary brain cancer. Top-line data from this interim analysis was previously announced to ASX on 7 April 2020.
29 May, 2020
Even if it's not a huge purchase, we think it was good to see that Iain Ross, the Independent Chairman of the Board of...
25 May, 2020
Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we...
07 Apr, 2020
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share positive interim data from its ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most common and most aggressive form of primary brain cancer.
24 Feb, 2020
James Garner became the CEO of Kazia Therapeutics Limited (ASX:KZA) in 2016. First, this article will compare CEO...
11 Dec, 2019
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it's lead program, GDC-0084, has been selected to join GBM AGILE, an international, academic-led, multi-drug adaptive phase II / III study in glioblastoma. It is expected that data from GBM AGILE will be used to seek marketing approval for GDC-0084 from FDA and other regulatory agencies.
28 Nov, 2019
The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...